| ○種別 (必須): | □ | 学術論文 (審査論文)
| [継承] |
| ○言語 (必須): | □ | 英語
| [継承] |
| ○招待 (推奨): |
| ○審査 (推奨): |
| ○カテゴリ (推奨): |
| ○共著種別 (推奨): |
| ○学究種別 (推奨): |
| ○組織 (推奨): |
| ○著者 (必須): | 1. | 大塚 憲司
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 2. | 軒原 浩
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 3. | 三橋 惇志 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.呼吸器・膠原病内科学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 4. | 尾崎 領彦 ([徳島大学.病院.診療科.内科.呼吸器・膠原病内科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 5. | (英) Yabuki Yohei (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 6. | 米田 浩人
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 7. | 荻野 広和 ([徳島大学.病院.診療科.内科.呼吸器・膠原病内科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 8. | 西岡 安彦 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.呼吸器・膠原病内科学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| ○題名 (必須): | □ | (英) Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease. (日)
| [継承] |
| ○副題 (任意): |
| ○要約 (任意): | □ | (英) Second-line chemotherapy among patients with NSCLC complicated by ILD showed a certain effectiveness, but some patients experienced the AE of ILD, which may lead to death. The risk of the AE of ILD must be considered especially for patients with UIP and low percentage VC. (日) Thirty-five patients received two or more regimens. Thirty-four patients were male and the median age at the initiation of second-line chemotherapy was 70 years. Almost all patients had a smoking history. Fourteen patients had adenocarcinoma and 15 had squamous cell carcinoma histology. Stages III and IV were observed in 20 and 11 patients, respectively. With respect to the type of ILD, 12 patients had usual interstitial pneumonia (UIP). The overall response rate and disease control rate were 11.4 and 68.6%, respectively. The median progression-free and median overall survival were 4.1 and 6.4 months, respectively. The AE of ILD was observed in eight patients, five of whom died. UIP and low percentage vital capacity were detected as significant risk factors for the AE of ILD.
| [継承] |
| ○キーワード (推奨): | 1. | (英) Humans (日) (読)
| [継承] |
| 2. | 男性 (male)
| [継承] |
| 3. | (英) Aged (日) (読)
| [継承] |
| 4. | 女性 (female)
| [継承] |
| 5. | (英) Carcinoma, Non-Small-Cell Lung (日) (読)
| [継承] |
| 6. | (英) Lung Neoplasms (日) (読)
| [継承] |
| 7. | (英) Retrospective Studies (日) (読)
| [継承] |
| 8. | (英) Lung Diseases, Interstitial (日) (読)
| [継承] |
| 9. | (英) Antineoplastic Combined Chemotherapy Protocols (日) (読)
| [継承] |
| ○発行所 (推奨): |
| ○誌名 (必須): | □ | Thoracic Cancer (Zhongguo kang ai xie hui Fei ai zhuan ye wei yuan hui/International Chinese Society of Thoracic Surgery/Tianjin Shi fei ai yan jiu suo)
(pISSN: 1759-7706, eISSN: 1759-7714)
| ○ISSN (任意): | □ | 1759-7714
ISSN: 1759-7706
(pISSN: 1759-7706, eISSN: 1759-7714) Title: Thoracic cancerTitle(ISO): Thorac CancerPublisher: John Wiley and Sons Inc (NLM Catalog)
(Scopus)
(CrossRef)
(Scopus information is found. [need login]) | [継承] |
| [継承] |
| ○巻 (必須): | □ | 13
| [継承] |
| ○号 (必須): | □ | 21
| [継承] |
| ○頁 (必須): | □ | 2978 2984
| [継承] |
| ○都市 (任意): |
| ○年月日 (必須): | □ | 西暦 2022年 9月 15日 (令和 4年 9月 15日)
| [継承] |
| ○URL (任意): |
| ○DOI (任意): | □ | 10.1111/1759-7714.14645 (→Scopusで検索)
| [継承] |
| ○PMID (任意): | □ | 36106507 (→Scopusで検索)
| [継承] |
| ○CRID (任意): |
| ○WOS (任意): |
| ○Scopus (任意): |
| ○評価値 (任意): |
| ○被引用数 (任意): |
| ○指導教員 (推奨): |
| ○備考 (任意): | 1. | (英) PublicationType: Journal Article (日)
| [継承] |